Skip to main content
. 2022 Jun 18;11(4):1609–1629. doi: 10.1007/s40121-022-00661-5

Table 2.

Infection characteristics in patients with IFIs during the study (FAS)

Isavuconazole (n = 510) Posaconazole (n = 540) Voriconazole (n = 491) Multiple/sequenced MAT therapies (n = 452) Total (N = 1993)
Patients with IFIsa 61 (12.0) 43 (8.0) 49 (10.0) 133 (29.4) 286 (14.4)
Highest level of IFI diagnosis, na 58 40 41 123 262
 Proven 26 (44.8) 23 (57.5) 15 (36.6) 65 (52.8) 129 (49.2)
 Probable 21 (36.2) 12 (30.0) 18 (43.9) 29 (23.6) 80 (30.5)
 Possible 11 (19.0) 5 (12.5) 8 (19.5) 29 (23.6) 53 (20.2)
Pathogen treated, nab 55 43 47 123 268
 Genus species
 Aspergillus 24 (43.6) 9 (20.9) 23 (48.9) 53 (43.1) 109 (40.7)
  fumigatus 10 (18.2) 6 (14.0) 12 (25.5) 14 (11.4) 42 (15.7)
  niger 1 (1.8) 1 (2.3) 2 (4.3) 9 (7.3) 13 (4.9)
  flavus 1 (1.8) 0 1 (2.1) 2 (1.6) 4 (1.5)
  versicolor 0 0 3 (6.4) 0 3 (1.1)
  Not specified 9 (16.4) 2 (4.7) 5 (10.6) 23 (18.7) 39 (14.6)
 Candida 17 (30.9) 14 (32.6) 12 (25.5) 22 (17.9) 65 (24.3)
  glabrata 8 (14.5) 9 (20.9) 4 (8.5) 6 (4.9) 27 (10.1)
  krusei 4 (7.3) 1 (2.3) 0 2 (1.6) 7 (2.6)
  parapsilosis 3 (5.5) 2 (4.7) 0 1 (0.8) 6 (2.2)
  albicans 2 (3.6) 5 (11.6) 7 (14.9) 8 (6.5) 22 (8.2)
  dubliniensis 1 (1.8) 0 1 (2.1) 3 (2.4) 5 (1.9)
  tropicalis 1 (1.8) 0 1 (2.1) 2 (1.6) 4 (1.5)
  Not specified 1 (1.8) 1 (2.3) 0 4 (3.3) 6 (2.2)
 Rhizopus 3 (5.5) 1 (2.3) 0 7 (5.7) 11 (4.1)
 Mucor 2 (3.6) 0 1 (2.1) 6 (4.9) 9 (3.4)
 Penicillium 1 (1.8) 1 (2.3) 1 (2.1) 3 (2.4) 6 (2.2)
 Coccidioides 1 (1.8) 9 (20.9) 0 3 (2.4) 13 (4.9)
 Histoplasma 1 (1.8) 0 4 (8.5) 5 (4.1) 10 (3.7)
  capsulatum 1 (1.8) 0 4 (8.5) 3 (2.4) 8 (3.0)
 Scedosporium 1 (1.8) 0 0 3 (2.4) 4 (1.5)
 Fusarium 0 2 (4.7) 1 (2.1) 7 (5.7) 10 (3.7)
 Other 7 (12.7) 7 (16.3) 6 (12.8) 19 (15.4) 39 (14.6)

Data are n (%), unless otherwise indicated

FAS full analysis set, IFI invasive fungal infection

aThe number of patients (n) with at least one IFI during the study and non-missing data for that parameter

bOnly incidences of ≥ 1% are shown